
|Videos|October 17, 2016
Actionable Mutations Impacting Breast Cancer Treatment
Author(s)Erin Wysong Hofstatter, MD
Erin Wysong Hofstatter, MD, associate professor at Yale Cancer Center and co-director of the Cancer Genetics and Prevention Program, discusses the actionable mutations that impact treatment and surgical decisions in breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































